Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Harvard Business School
Julphar
Medtronic
McKesson
Queensland Health
Deloitte
Healthtrust
Farmers Insurance

Generated: May 25, 2018

DrugPatentWatch Database Preview

AVODART Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Avodart patents expire, and what generic alternatives are available?

Avodart is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in AVODART is dutasteride. There are seventeen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the dutasteride profile page.
Drug patent expirations by year for AVODART
Pharmacology for AVODART
Medical Subject Heading (MeSH) Categories for AVODART
Synonyms for AVODART
(1S,2R,7R,10S,11S,14S,15S)-N-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide
(1S,2R,7R,10S,11S,14S,15S)-N-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-3-ene-14-carboxamide
(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(2,5-Bis(trifluoromethyl)phenyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5.alpha.,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride;Avodart;
(5|A,17|A)-N-{2,5-Bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-l-ene-17-carboxamide
(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5alpha,17beta)-N-{2,5-bis(trifluoromethyl)-phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
164656-23-9
1H-Indeno(5,4-f)quinoline-7-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
656D239
AB01274774_02
AB01274774-01
AB1009276
AC1OCF98
AK-72895
AKOS015920136
AKOS015924431
alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
AOB5568
Avidart
Avidart (TN)
Avodart (TN)
Avodart, Dutasteride
Avolve
Avolve (TN)
B-2151
BCP9000630
BCPP000248
BDBM50340481
Bio-0167
BR-72895
C-23099
C27H30F6N2O2
CAS-164656-23-9
CC-27419
CHEBI:521033
CHEMBL1200969
CS-1542
D03820
D0A9YA
DB01126
DSSTox_CID_26452
DSSTox_GSID_46452
DSSTox_RID_81626
DTXSID8046452
Duagen
Duagen (TN)
Duprost (TN)
Dutagen (TN)
Dutas (TN)
Dutasteride
Dutasteride (JAN/USAN/INN)
Dutasteride [USAN:INN:BAN]
Dutasteride [USAN]
Dutasteride for system suitability, European Pharmacopoeia (EP) Reference Standard
Dutasteride, >=98% (HPLC)
Dutasteride, European Pharmacopoeia (EP) Reference Standard
Dutasteride, United States Pharmacopeia (USP) Reference Standard
FT-0080365
GG 745
GG-745
GG745
GI 198745
GI-198745
GI-198745X
GI198745
GS-3565
GTPL7457
HY-13613
J10036
JWJOTENAMICLJG-QWBYCMEYSA-N
KB-95466
MCULE-1602474627
MFCD09843955
MolPort-003-847-041
N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
NCGC00164571-01
NSC-740477
NSC740477
O0J6XJN02I
Q-201052
RL02115
s1202
SC-08812
SCHEMBL5903
ST24026289
Tox21_112199
UNII-O0J6XJN02I
veltride
Z1563146168
ZINC3932831

US Patents and Regulatory Information for AVODART

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline AVODART dutasteride CAPSULE;ORAL 021319-001 Nov 20, 2001 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for AVODART

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline AVODART dutasteride CAPSULE;ORAL 021319-001 Nov 20, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline AVODART dutasteride CAPSULE;ORAL 021319-001 Nov 20, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline AVODART dutasteride CAPSULE;ORAL 021319-001 Nov 20, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for AVODART
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 0.5 mg ➤ Subscribe 2007-10-29

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cerilliant
UBS
McKinsey
Healthtrust
McKesson
Teva
Chubb
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.